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Introduction
Lobular Neoplasia (LN) is an incidental finding
on breast biopsy which represents a collection
of round, monomorphic, dyshesive cells with
increased cytoplasmic nuclear ratio. LN is classified
as a range from Atypical Lobular Hyperplasia (ALH)
to Lobular Carcinoma In-Situ (LCIS). These lesions
are known to have an associated higher relative
risk of subsequent carcinoma bilaterally (eight-tonine fold and four-to-five fold increases for LCIS
and ALH, respectively). While numerous past studies
have shown a high upgrade rate to cancer of 1040%, these studies may be limited. Newer studies
show a rate of 1-3%. Institutional protocols have
recently changed such that close clinical follow-up
of LN is warranted instead of excisional biopsy.

Results
A total of 1271 patient cases were reviewed from the radiology technician log. Females comprised 97.7% of
patients. Ultrasound biopsy guidance was performed in 75% of cases compared with 25% using stereotactic
(Table 1, Figure 1). Biopsy was not performed on 67 cases, and core biopsy results were reviewed in 1204
cases. LN as the highest-risk lesion was found in 15 cases (4 were LCIS and 11 were ALH), equivalent to
1.3% of all cases (Table 2). Of the 15 cases with LN, 12 elected to have excisional biopsy at LVHN of which 2
(17%) were upgraded to a cancer diagnosis (Table 3).
Figure 1. Consort Diagram

Table 1. Demographic Data and Baseline Characteristics
Parameter

Sample (N=1271)
% (N)

Total cases reviewed
n=1271

Gender

99.7 (1267)
0.3 (4)

Female
Male

No core biopsy
n=67

Biopsy Guidance Method

75 (957)
25 (314)

Sonographic
Stereotactic

No LN (or higher-risk
lesion present)
n=1189

Parameter

Concordant Lobular Neoplasia
ALH
LCIS

Sample (N=1204)
% (N)

Table 2. Excisional Biopsy Results of Lesions with LN
Sample (N=12)
% (N)

Preoperative Diagnosis (core biopsy)

75 (9)
25 (3)

ALH
LCIS
Postoperative Diagnosis (excisional biopsy)
Cancer (upgrade)
Same as preoperative
diagnosis (no upgrade)

This study is a retrospective review of 27 months
of stereotactic and ultrasound guided core biopsies.
Biopsy cases were identified through logs kept by
radiology technicians at Breast Health Services at
LVHN. Cases were determined to be ineligible for
the study if a biopsy was started but not completed
or if the procedure was a cyst or hematoma
drainage. Each case was reviewed for LN within the
pathology report of the Electronic Medical Record
(EMR). LN was noted if it was found to be the
highest-risk lesion on core biopsy. If LN was found,
the case was then checked for a follow-up surgical
excisional biopsy. If there was an excisional biopsy,
it was determined whether the lesion was upgraded
to cancer according to the pathology report within
the EMR. This study was determined by the project
team to be exempt from Internal Review Board (IRB)
approval because it was recorded in such a manner
where subjects cannot be identified, it has no risk
to patients, it involves the collection of existing data,
and it seeks to improve the management of LN at
LVHN while comparing to the established standard.

Upgrade to cancer
n=2

98.7 (1185)
1.3 (15)
0.9 (11)
0.3 (4)

*Either no LN, or LN is compounded by a worse non-benign lesion
of the breast.

Parameter

Methodology

Follow-up excisional
biops
n=12

Results of Core Biopsy
Not Lobular Neoplasia*

By determining the baseline upgrade rate from
LN on core biopsy to cancer at excision biopsy for
women at Lehigh Valley Health Network (LVHN), we
can compare to the upgrade rate in recent literature
and have a better understanding of the risks of LN
within the LVHN population.

Highest-risk lesion is
LN
n=15

No follow-up
excisional biopsy
n=3

Table 2. Core Biopsy Results

Problem Statement

Core biopsy
n=1204

17/(2)
83 (10)

No cancer
n=10

Figure 2. Biopsy Type and Core Pathology Results
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Conclusions and Future Implications
There is no clear consensus regarding the implications of LN and future management when it is the highestrisk lesion found at core biopsy. The patients in this study had core biopsies with LN as the highest-risk lesion
in 15 cases, or 1.3% of cases, which is on-par with past studies (between 0.5 and 3.8%). Out of LN cases that
underwent excisional biopsy, upgrade to cancer occurred in 2 (17%). While this is high, these 2 cases would
heavily favor excision regardless of the diagnosis of LN due to discordant imaging and pathology. Overall, these
results support the current protocol of close imaging follow-up, and further discussion in accordance with the
patient’s goals.
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